cbdMD Inc. (NYSE American: YCBD) reported net sales of $5.6 million for the second quarter of fiscal 2026, representing a 19% increase compared to $4.7 million in the same period last year. The Charlotte-based CBD company also posted 12% sequential revenue growth from the first quarter of fiscal 2026.

The company recorded a net loss attributable to common shareholders of $876,783, or $0.08 per share, for the quarter ended March 31, 2026. This compared to a net loss of $1.5 million, or $1.90 per share, in the second quarter of fiscal 2025.

cbdMD completed the acquisition of Bluebird Botanicals in mid-January 2026. The acquisition contributed to revenue growth, though integration costs created an earnings impact during the quarter. The company reported that Bluebird began generating positive income in March.

Direct-to-consumer sales totaled $3.8 million, representing 67% of total net sales and a 4% increase from the prior year. Wholesale net sales reached $1.8 million, or 33% of total sales, marking a 65% increase year-over-year.

The company's loss from operations was $801,000 compared to $485,000 in the prior year period. Non-GAAP adjusted EBITDA loss was approximately $220,000 versus $197,000 in the second quarter of fiscal 2025.

cbdMD reported working capital of $5.4 million and cash on hand of $2.6 million as of March 31, 2026, compared to working capital of $3.3 million and cash of $2.2 million at September 30, 2025.

The Centers for Medicare & Medicaid Services activated a pathway for hemp-derived CBD products through the Beneficiary Enhancement Initiative on April 1, 2026. The program allows approved participants to furnish eligible hemp-derived products to beneficiaries at up to $500 annually per eligible beneficiary.